Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6687144 | 0.82 | DGAT1 (0.33) | — | |
| SCHEMBL515150 | 0.82 | NQO2 (0.35) | NQO2 | |
| SCHEMBL13550061 | 0.75 | RAPGEF4 (0.34) | NQO2 | |
| SCHEMBL13550059 | 0.75 | NQO2 (0.32) | NQO2 | |
| SCHEMBL12074048 | 0.75 | RAPGEF4 (0.40) | — | |
| SCHEMBL17733622 | 0.75 | TTR (0.32) | — | |
| SCHEMBL12699692 | 0.75 | CYP3A4 (0.38) | NQO2 | |
| SCHEMBL5305665 | 0.75 | HDAC1 (0.35) | NQO2 | |
| SCHEMBL12648816 | 0.75 | RAPGEF4 (0.40) | — | |
| SCHEMBL29603436 | 0.75 | RAPGEF4 (0.34) | NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-118530732-A | Isothiocyanate liquid crystal material and application thereof | 华为技术有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-20240247014-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS, INC. | 2024-07-25 | — | — | US | disclosed |
| WO-2024112796-A1 | MODULATORS OF TNF-α ACTIVITY | FORWARD THERAPEUTICS, INC. (US) | 2024-05-30 | — | — | WO | disclosed |
| US-9296948-B2 | Mesogenic compounds, liquid-crystalline media and components for high-frequency technology | MERCK PATENT GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-9296948-B2 | Mesogenic compounds, liquid-crystalline media and components for high-frequency technology | MERCK PATENT GMBH (DE) | 2016-03-29 | — | — | US | disclosed |
| US-20140021405-A1 | MESOGENIC COMPOUNDS, LIQUID-CRYSTALLINE MEDIA AND COMPONENTS FOR HIGH-FREQUENCY TECHNOLOGY | MERCK PATENT GMBH (DE) | 2014-01-23 | — | — | US | disclosed |
| US-20140021405-A1 | MESOGENIC COMPOUNDS, LIQUID-CRYSTALLINE MEDIA AND COMPONENTS FOR HIGH-FREQUENCY TECHNOLOGY | MERCK PATENT GMBH (DE) | 2014-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12384808-B2 | Modulators of TNF-α activity | TNF, NFKBIA, TNFRSF1A | NQO2 759/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | NQO2 904/4885 |
| US-20240247014-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | NQO2 904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.